Kazia Therapeutics Limited
KZIA
$13.16
-$0.67-4.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | 0.33% | -94.67% | |||
| Total Revenue | 0.33% | -94.80% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 0.33% | -94.80% | |||
| SG&A Expenses | 0.32% | 142.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.32% | 107.94% | |||
| Operating Income | -0.32% | -183.49% | |||
| Income Before Tax | -0.32% | -8.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.32% | -25.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.32% | -25.10% | |||
| EBIT | -0.32% | -183.49% | |||
| EBITDA | -0.32% | -202.83% | |||
| EPS Basic | -0.32% | 46.22% | |||
| Normalized Basic EPS | -0.32% | -4.31% | |||
| EPS Diluted | -0.32% | 46.19% | |||
| Normalized Diluted EPS | -0.32% | -4.31% | |||
| Average Basic Shares Outstanding | 0.00% | 132.62% | |||
| Average Diluted Shares Outstanding | 0.00% | 138.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||